D-0983-2017 Class III Terminated
FDA drug recall D-0983-2017 was initiated by Teva Pharmaceuticals USA on Jun 29, 2017 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: out of specification test results for related compounds largest unknown impurity. The recall status is terminated (terminated Apr 26, 2018). Affected quantity: 25264 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 26, 2017
- Initiation Date
- Jun 29, 2017
- Termination Date
- Apr 26, 2018
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 25264 bottles
Product description
Buprenorphine and Naloxone Sublingual Tablets, 2 mg/0.5 mg 30 tablets per bottle, Rx only, Distributed by: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0093-5720-56
Reason for recall
Failed Impurities/Degradation Specifications: out of specification test results for related compounds largest unknown impurity.
Distribution pattern
Nationwide in the USA
Code information
Lot #: 30227613A, 30227614A, 30227615A, EXP 6/2017; 30228559A, 30228560A, EXP 9/2017; 3000123, EXP 7/2018
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0983-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026